These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 9164208

  • 1. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
    Gordon AN, Stringer CA, Matthews CM, Willis DL, Nemunaitis J.
    J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208
    [Abstract] [Full Text] [Related]

  • 2. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A, Mendiola C, del Campo JM, Massuti B, Casado A, Escobedo A, Moyano A, Ojeda B, Poveda A, Benito D.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
    Sparano JA, Robert N, Silverman P, Lazarus H, Malik U, Venkatraj U, Sarta C.
    J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA.
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [Abstract] [Full Text] [Related]

  • 10. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [Abstract] [Full Text] [Related]

  • 12. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [Abstract] [Full Text] [Related]

  • 13. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ, Millenson M, O'Dwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R.
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [Abstract] [Full Text] [Related]

  • 14. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA.
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [Abstract] [Full Text] [Related]

  • 15. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A, Salzano E.
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
    Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL.
    J Clin Oncol; 1995 Sep; 13(9):2230-7. PubMed ID: 7545219
    [Abstract] [Full Text] [Related]

  • 18. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
    Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D.
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.
    Meerpohl HG, du Bois A, Luck HJ, Kühnle H, Möbus V, Kreienberg R, Bauknecht T, Köchli O, Bochtler H, Diergarten K.
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330
    [Abstract] [Full Text] [Related]

  • 20. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF, Michelotti A, Baldini E, Tibaldi C, DaPrato M, Salvadori B, Giannessi PG, Gentile A, Biadi O, Mariani M.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.